Medicamen Biotech Soars 11% on European Market Deal with Denmark’s XGX Pharma

Medicamen Biotech Limited, a key player in the pharmaceutical sector, witnessed an 11% surge in its stock price during Tuesday’s trading session, marking a significant uptick in investor confidence. This sharp rise came after the company announced a distribution agreement with Denmark-based XGX Pharma, further bolstering its presence in the European market.

The deal, which was disclosed through the company’s regulatory filings, involves the marketing of three critical pharmaceutical products across Europe. The products include two oncology treatments: Temozolomide Capsules 250 mg and Bortezomib 3.5 mg Injection (1 vial), as well as a Beta-lactam formulation: Amoxicillin Oral Dispersible Tablets 250 mg. As part of the agreement, Medicamen Biotech will hold the Marketing Authorizations for these products, which is a pivotal role in ensuring their regulatory approval and market accessibility.

Price Movement and Stock Performance

At 02:08 p.m. on the day of the announcement, Medicamen’s stock was trading at Rs. 495, up by nearly 7.5% from its previous closing price of Rs. 460.7. With a market capitalization of Rs. 629.4 crores, this uptick added significant value to the company’s stock, which has delivered a robust 14% return over the last year. Over the past month, the stock gained approximately 11%, further demonstrating the positive momentum.

What’s Behind the Surge?

The surge in Medicamen’s stock price can be attributed to the strategic nature of the distribution agreement with XGX Pharma. The partnership aligns well with the company’s goals of expanding its global footprint, particularly in the high-demand European market. By securing the rights to market these high-value oncology and beta-lactam drugs, Medicamen has significantly bolstered its portfolio and growth prospects.

Previous Updates and Growth Outlook

This announcement follows a series of promising developments for Medicamen Biotech. On March 7, the company signed an agreement with a South African business conglomerate to register and market its products in the region, tapping into the $4 billion pharmaceutical market. Additionally, on April 3, Medicamen entered into a Contract Development and Manufacturing Organization (CDMO) agreement with XGX Pharma to develop and manufacture six products for the European market. These agreements highlight the company’s ongoing efforts to expand its international reach and diversify its product offerings.

Financial Snapshot

While the news of the distribution agreement is positive, Medicamen Biotech’s recent financials show a slight dip in revenue. The company reported a marginal decline of approximately 3% in its Q3 FY25 revenue—from Rs. 46.5 crores in Q3 FY24 to Rs. 45.2 crores in Q3 FY25. Despite this, the long-term outlook remains positive, especially with the new partnerships and strategic moves aimed at enhancing growth across multiple international markets.

This news marks a significant step forward for Medicamen Biotech, as the company continues to expand its global footprint and diversify its product portfolio. The distribution agreement with XGX Pharma is a notable achievement and highlights the company’s commitment to broadening its reach in the highly competitive European pharmaceutical market.

Medicamen Biotech’s 11% stock surge following the announcement of its distribution deal with XGX Pharma underscores investor optimism about the company’s growth potential in the European market. With its strong market positioning and continued expansion efforts, Medicamen Biotech is poised for a promising future in the global pharmaceutical landscape.

{Source Trade Brains}

Follow Joburg ETC on Facebook, Twitter , TikTok and Instagram

For more News in Johannesburg, visit joburgetc.com